AptarGroupATR -0.36%82 Return-on-Tangible-Equity is 21.96% as of Mar. 2026, which is 31% below its 10-year median of 31.86. GuruFocus rates ATR with a GF Score™ of 82/100 and a GF Value™ of $157.01 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 758 Medical Devices & Instruments companies, AptarGroup ranks better than 88.26% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. AptarGroup's annualized net income for the quarter that ended in Mar. 2026 was $291 Mil. AptarGroup's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $1,324 Mil. Therefore, AptarGroup's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 21.96%.
The historical rank and industry rank for AptarGroup's Return-on-Tangible-Equity or its related term are showing as below:
ATR'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 27.79 Med: 31.86 Max: 49.79
Current: 28.11
During the past 13 years, AptarGroup's highest Return-on-Tangible-Equity was 49.79%. The lowest was 27.79%. And the median was 31.86%.
ATR's Return-on-Tangible-Equity is ranked better than 88.26% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs ATR: 28.11
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
AptarGroup Return-on-Tangible-Equity Related Terms
AptarGroup Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for AptarGroup's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATR vs RGEN, AVTR, TFX: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, AptarGroup's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AptarGroup Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AptarGroup's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where AptarGroup's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 21.96% mean?
AptarGroup (ATR) has a Return-on-Tangible-Equity of 21.96% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AptarGroup and its competitors. This is 31% below median its historical median of 31.86. Over the past decade, AptarGroup's Return-on-Tangible-Equity has ranged from 27.79 to 49.79. According to the industry distribution chart, AptarGroup ranks #89 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 11.7%.
Is AptarGroup's Return-on-Tangible-Equity too high?
AptarGroup's current Return-on-Tangible-Equity of 21.96% is 31% below median its 10-year median of 31.86. Over the past 10 years, this metric has ranged from a low of 27.79 to a high of 49.79. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. AptarGroup's value of 21.96% is 438.2% above this industry median. Based on the distribution chart, AptarGroup ranks #89 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AptarGroup has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AptarGroup's Return-on-Tangible-Equity compare to RGEN and AVTR?
According to the Medical Devices & Instruments industry distribution chart, AptarGroup ranks #89 out of 758 companies for Return-on-Tangible-Equity. This places AptarGroup in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.08. AptarGroup's value of 21.96% is 438.2% above this benchmark. Historically, AptarGroup's own Return-on-Tangible-Equity has ranged from 27.79 to 49.79 over the past decade. While the company's 10-year median is 31.86 vs. the industry median of 4.08, AptarGroup has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AptarGroup's current Return-on-Tangible-Equity of 21.96% is 438.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AptarGroup and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AptarGroup's current Return-on-Tangible-Equity is 21.96%, which is 31% below median its own 10-year median of 31.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AptarGroup stock overvalued right now?
Based on GuruFocus' analysis, AptarGroup (ATR) is currently considered Modestly Undervalued. The stock's GF Value™ is $157.01, compared to a current price of $125.98 — trading 19.8% below its estimated fair value. The current Return-on-Tangible-Equity is 21.96%, which is 31% below median its 10-year median of 31.86 and 438.2% above the Medical Devices & Instruments industry median of 4.08. AptarGroup's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For AptarGroup (ATR), the current Return-on-Tangible-Equity is 21.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AptarGroup (ATR) Overvalued in 2026?
Based on GuruFocus' analysis, AptarGroup stock appears to be undervalued.
The current stock price of $125.98 is trading 19.8% below its estimated GF Value™ of $157.01.
GuruFocus considers AptarGroup to be Modestly Undervalued.
Key valuation signals for ATR:
Return-on-Tangible-Equity: 21.96% (31% below median its 10-year median of 31.86)
GF Value™: $157.01 vs. price of $125.98 (19.8% below fair value)
Industry Position: 438.2% above the Medical Devices & Instruments median (#89 of 758)
No single metric tells the full story. See the ATR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
82GF Score
Get the complete analysis for ATR
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATR has been successfully added to your 
